LivaNova PLC $LIVN Stock Holdings Lifted by Martingale Asset Management L P

Key Points

• Martingale Asset Management increased its holdings in LivaNova PLC by 207.7%, acquiring an additional 51,022 shares, bringing their total to 75,583 shares valued at approximately $2.97 million.
• LivaNova's stock has received upgrades from multiple analysts, with Barclays raising its price target from $55 to $58, and Needham & Company setting a new target of $64, contributing to a consensus rating of "Buy."
• The company reported positive earnings of $1.05 per share for the last quarter, surpassing estimates and indicating a year-over-year revenue increase of 10.6% to $352.5 million.

Martingale Asset Management L P boosted its stake in LivaNova PLC (NASDAQ:LIVN - Free Report) by 207.7% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 75,583 shares of the company's stock after purchasing an additional 51,022 shares during the period. Martingale Asset Management L P owned approximately 0.14% of LivaNova worth $2,969,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also modified their holdings of LIVN. Russell Investments Group Ltd. increased its holdings in shares of LivaNova by 17.1% in the 4th quarter. Russell Investments Group Ltd. now owns 1,502 shares of the company's stock valued at $70,000 after acquiring an additional 219 shares during the last quarter. Central Pacific Bank Trust Division boosted its holdings in LivaNova by 7.0% in the first quarter. Central Pacific Bank Trust Division now owns 4,407 shares of the company's stock worth $173,000 after purchasing an additional 290 shares during the period. CWM LLC increased its stake in LivaNova by 52.3% during the first quarter. CWM LLC now owns 871 shares of the company's stock valued at $34,000 after purchasing an additional 299 shares during the last quarter. Mariner LLC increased its stake in LivaNova by 8.4% during the fourth quarter. Mariner LLC now owns 5,741 shares of the company's stock valued at $266,000 after purchasing an additional 446 shares during the last quarter. Finally, DekaBank Deutsche Girozentrale raised its holdings in shares of LivaNova by 2.4% during the first quarter. DekaBank Deutsche Girozentrale now owns 21,000 shares of the company's stock worth $817,000 after purchasing an additional 500 shares during the period. 97.64% of the stock is owned by hedge funds and other institutional investors.

LivaNova Price Performance

Shares of NASDAQ:LIVN traded up $0.27 during trading on Tuesday, reaching $56.62. The company had a trading volume of 454,463 shares, compared to its average volume of 707,137. LivaNova PLC has a twelve month low of $32.48 and a twelve month high of $57.35. The company has a debt-to-equity ratio of 0.31, a quick ratio of 1.09 and a current ratio of 1.29. The firm has a market capitalization of $3.09 billion, a PE ratio of -14.56 and a beta of 0.92. The firm's fifty day moving average is $46.64 and its 200 day moving average is $43.06.

LivaNova (NASDAQ:LIVN - Get Free Report) last issued its quarterly earnings results on Wednesday, August 6th. The company reported $1.05 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.84 by $0.21. The company had revenue of $352.50 million for the quarter, compared to analysts' expectations of $332.20 million. LivaNova had a positive return on equity of 14.57% and a negative net margin of 16.13%.The firm's revenue for the quarter was up 10.6% on a year-over-year basis. During the same period last year, the firm earned $0.93 EPS. On average, equities analysts forecast that LivaNova PLC will post 2.85 EPS for the current year.

Wall Street Analyst Weigh In

A number of equities research analysts recently weighed in on LIVN shares. Needham & Company LLC reaffirmed a "buy" rating and set a $64.00 price objective on shares of LivaNova in a research report on Tuesday, May 13th. Barclays lifted their target price on LivaNova from $55.00 to $58.00 and gave the company an "equal weight" rating in a research note on Thursday, August 21st. Robert W. Baird increased their price target on LivaNova from $55.00 to $61.00 and gave the stock an "outperform" rating in a research report on Thursday, May 8th. Wolfe Research raised LivaNova from a "peer perform" rating to an "outperform" rating and set a $60.00 price target on the stock in a report on Tuesday, May 20th. Finally, Wall Street Zen upgraded LivaNova from a "buy" rating to a "strong-buy" rating in a research note on Saturday, August 9th. One analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and one has issued a Hold rating to the stock. According to MarketBeat.com, the company has a consensus rating of "Buy" and a consensus target price of $59.71.

LivaNova Company Profile

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.